ArticleBlood2017
Molecular synergy underlies the co-occurrence patterns and phenotype of
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 94 citations in OpenAlex.
- Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells.Leukemia · 2026Article
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Article
- The Mutational Landscape of Acute Myeloid Leukemia and Its Impact.International journal of molecular sciences · 2026Review
- Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein.Nature biotechnology · 2026Article
- FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.NPJ precision oncology · 2026Article
- Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia.JCI insight · 2026Article
- Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.Frontiers in medicine · 2026Review
- Article
- Enforcement of stem-cell dormancy by nucleophosmin mutation is a critical determinant of unrestricted self-renewal during myeloid leukemogenesis.Haematologica · 2025Article
- Joint representation and visualization of derailed cell states with Decipher.Genome biology · 2025Article
- Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia.Leukemia · 2025Article
- Pbx3-mediated suppression of type I interferon response contributes to leukemia progression driven by MLL-AF9.Cancer gene therapy · 2025Article
- Review
- The Clinical Impact of NPM1 Mutations and the Effect of Concurrent Mutations in Acute Myeloid Leukemia: Unraveling the Prognostic Significance.Health science reports · 2024Article
- Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.Journal of hematology & oncology · 2024Review
- In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.Cancer cell · 2024Article
- Recent advances in AML with mutated NPM1.International journal of hematology · 2024Review
- Characteristics and Prognosis of "Acute Promyelocytic Leukemia-like" Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort.Biomedicines · 2024Article
- Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.Science advances · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 9 institutions in 4 countries.
Oliver M DoveyWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Jonathan L CooperWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Annalisa MupoWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Carolyn S GroveWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Claire LynnLeukemia and Stem Cell Biology Group, Division of Cancer Studies, Department of Haematological Medicine, King's College London, London, United Kingdom.
Nathalie ConteSample Phenotype Ontology Team, European Bioinformatics Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Robert M AndrewsInstitute of Translation, Innovation, Methodology, and Engagement, Cardiff University School of Medicine, Cardiff, United Kingdom.
Suruchi PacharneWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Konstantinos TzelepisWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
M S VijayabaskarWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Paul GreenWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Roland RadDepartment of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Mark ArendsCancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Penny WrightDepartment of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; and.
Kosuke YusaWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Allan BradleyWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.
Ignacio VarelaInstituto de Biomedicina y Biotecnología de Cantabria, Santander, Spain.
George S VassiliouWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, United Kingdom.ORCID 0000-0003-4337-8022
Wellcome Sanger Institute · GBCambridge University Hospitals NHS Foundation Trust · GBCardiff University · GBEdinburgh Cancer Research · GBEuropean Bioinformatics Institute · GBGerman Cancer Research Center · DEInstituto de Biomedicina y Biotecnología de Cantabria · ESKing's College London · GBThe University of Western Australia · AU
Funding
Cancer Research UK 23015Medical Research Council MC_PC_12009Wellcome TrustWellcome Trust WT095663MA
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesAnimalsCell DifferentiationCell Self RenewalCell SurvivalDisease Progressionfms-Like Tyrosine Kinase 3Gene DosageGene Expression ProfilingGene Expression Regulation, LeukemicGene Expression Regulation, NeoplasticHematopoietic Stem CellsHomeodomain ProteinsHumansLeukemia, Myeloid, AcuteMicefms-Like Tyrosine Kinase 3Homeodomain ProteinsNKX2-3 protein, humanNPM1 protein, humanNpm1 protein, mouseNuclear ProteinsNucleophosminTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.